$ 23.84
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of SMMT is 32 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
